ATE283286T1 - Adnf mischungen zur verbesserung der lernfähigkeit und der gedächtnisfunktion - Google Patents

Adnf mischungen zur verbesserung der lernfähigkeit und der gedächtnisfunktion

Info

Publication number
ATE283286T1
ATE283286T1 AT01941783T AT01941783T ATE283286T1 AT E283286 T1 ATE283286 T1 AT E283286T1 AT 01941783 T AT01941783 T AT 01941783T AT 01941783 T AT01941783 T AT 01941783T AT E283286 T1 ATE283286 T1 AT E283286T1
Authority
AT
Austria
Prior art keywords
adnf
blends
memory function
improve learning
learning
Prior art date
Application number
AT01941783T
Other languages
English (en)
Inventor
Catherine Y Spong
Douglas Brenneman
Illana Gozes
Original Assignee
Us Gov Health & Human Serv
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Univ Ramot filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE283286T1 publication Critical patent/ATE283286T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Addiction (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
AT01941783T 2000-05-31 2001-05-31 Adnf mischungen zur verbesserung der lernfähigkeit und der gedächtnisfunktion ATE283286T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20894400P 2000-05-31 2000-05-31
US26780501P 2001-02-08 2001-02-08
PCT/US2001/017758 WO2001092333A2 (en) 2000-05-31 2001-05-31 Use of adnf for enhancing learning and memory

Publications (1)

Publication Number Publication Date
ATE283286T1 true ATE283286T1 (de) 2004-12-15

Family

ID=26903662

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01941783T ATE283286T1 (de) 2000-05-31 2001-05-31 Adnf mischungen zur verbesserung der lernfähigkeit und der gedächtnisfunktion

Country Status (11)

Country Link
US (2) US7427598B2 (de)
EP (1) EP1285000B1 (de)
JP (1) JP4440536B2 (de)
CN (1) CN1444600A (de)
AT (1) ATE283286T1 (de)
AU (2) AU7511101A (de)
CA (1) CA2410735A1 (de)
DE (1) DE60107416T2 (de)
MX (1) MXPA02011923A (de)
NZ (1) NZ522821A (de)
WO (1) WO2001092333A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613740B1 (en) * 1997-02-07 2003-09-02 Ramot University Authority For Applied Research And Industrial Development Ltd. Activity dependent neurotrophic factor III (ADNF III)
US7384908B1 (en) 1999-08-18 2008-06-10 National Institute Of Health Orally active peptides that prevent cell damage and death
AU7511101A (en) * 2000-05-31 2001-12-11 Us Gov Health & Human Serv Use of activity-dependent neurotrophic factor-derived polypeptides for enhancinglearning and memory: pre- and post-natal administration
WO2003022226A2 (en) * 2001-09-12 2003-03-20 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Neurotrophic components of the adnf i complex
MXPA05008487A (es) * 2003-02-10 2006-03-10 To Bbb Holding B V Acidos nucleicos expresados en forma diferencial en la barrera hemato-encefalica bajo condiciones de inflamacion.
WO2004080957A2 (en) 2003-03-12 2004-09-23 Ramot At Tel Aviv University Ltd. Use of adnf polypeptides for treating anxiety and depression
JP4878551B2 (ja) 2004-04-08 2012-02-15 貞和 相磯 運動ニューロン疾患治療薬
EP1885389A4 (de) 2005-03-23 2012-04-04 Univ Ramot Verwendung von adnf-polypeptiden zur behandlung von peripherer neurotoxizität
TWI303567B (en) * 2005-12-20 2008-12-01 Ind Tech Res Inst Oligopeptide, derivative thereof, and pharmaceutical composition comprising the same
US20070185035A1 (en) * 2005-12-23 2007-08-09 Nastech Pharmaceutical Company Inc. Enhanced mucosal administration of neuroprotective peptides
US8067369B2 (en) * 2006-02-24 2011-11-29 Ramot At Tel-Aviv University Protection of the retina against laser injury by NAP and related peptides
NZ583260A (en) * 2007-08-24 2012-07-27 Univ Ramot Neuroprotection using nap-like and sal-like peptide mimetics
US8586548B2 (en) 2009-08-17 2013-11-19 Ramot At Tel-Aviv University, Ltd. NAP alpha-aminoisobutyric acid analog with neuroprotective activity
US9518994B2 (en) 2010-01-06 2016-12-13 Ramot At Tel Aviv University Method for diagnosing and monitoring schizophrenia and tauopathies
WO2012015910A2 (en) * 2010-07-28 2012-02-02 Allon Therapeutics Inc. Use of adnf polypeptides for treating neurodegenerative diseases
EP3377089B1 (de) * 2015-11-18 2020-04-08 Herantis Pharma Plc Zusammensetzungen mit cdnf zur verwendung bei der intranasalen behandlung von erkrankungen des zentralnervensystems

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4587046A (en) * 1982-05-18 1986-05-06 The Regents Of The University Of California Drug-carrier conjugates
US6174862B1 (en) * 1991-04-22 2001-01-16 Ramot University Authority For Applied Research And Industrial Development, Ltd. Neurotrophic peptides of activity dependent neurotrophic factor
US5767240A (en) 1991-04-22 1998-06-16 The United States Of America As Represented By The Department Of Health And Human Services Activity-dependent neurotrophic factor
US6310040B1 (en) * 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
CA2135306A1 (en) * 1992-05-08 1993-11-25 Bradford A. Jameson Igf-1 analogs
ES2331595T3 (es) 1997-02-07 2010-01-08 The Government Of The Usa As Represented By The Secretary Of Department Of Health And Human Services Factor neurotrofico dependiente de actividad iii (adnf iii).
US6613740B1 (en) 1997-02-07 2003-09-02 Ramot University Authority For Applied Research And Industrial Development Ltd. Activity dependent neurotrophic factor III (ADNF III)
US6933277B2 (en) 1999-03-12 2005-08-23 The United States Of America As Represented By The Department Of Health And Human Services Prevention of fetal alcohol syndrome and neuronal cell death with ADNF polypeptides
US7384908B1 (en) * 1999-08-18 2008-06-10 National Institute Of Health Orally active peptides that prevent cell damage and death
WO2001012654A2 (en) 1999-08-18 2001-02-22 Ramot University Authority For Applied Research & Industrial Development Ltd. Orally active peptides that prevent cell damage and death
AU7511101A (en) * 2000-05-31 2001-12-11 Us Gov Health & Human Serv Use of activity-dependent neurotrophic factor-derived polypeptides for enhancinglearning and memory: pre- and post-natal administration

Also Published As

Publication number Publication date
US20090203615A1 (en) 2009-08-13
EP1285000B1 (de) 2004-11-24
CN1444600A (zh) 2003-09-24
HK1054947A1 (en) 2003-12-19
NZ522821A (en) 2004-08-27
AU2001275111B2 (en) 2006-07-06
DE60107416D1 (de) 2004-12-30
US20040048801A1 (en) 2004-03-11
US7427598B2 (en) 2008-09-23
WO2001092333A3 (en) 2002-05-30
CA2410735A1 (en) 2001-12-06
AU7511101A (en) 2001-12-11
EP1285000A2 (de) 2003-02-26
MXPA02011923A (es) 2004-09-06
DE60107416T2 (de) 2005-12-01
JP4440536B2 (ja) 2010-03-24
JP2003535105A (ja) 2003-11-25
WO2001092333A2 (en) 2001-12-06

Similar Documents

Publication Publication Date Title
DE60107416D1 (de) Adnf mischungen zur verbesserung der lernfähigkeit und der gedächtnisfunktion
DE60019458D1 (de) Stabilisierendes verdünnungsmittel für polypeptide und antigene
EP1266025A4 (de) Proteingerüste für antikörper-mimetika und andere bindungsproteine
DK1482042T3 (da) Aktive og inaktive CC-kemokinreceptorer og nukleinsyremolekyler der koder for receptoren
DE59903410D1 (de) Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
CY1107821T1 (el) Πολυπεπτιδιο παραγοντα viii με ενεργοτητα παραγοντα viii:c
DE69829293D1 (de) Verwendung eines mittels zur verminderung des risikos kardiovaskulärer erkrankungen
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
WO2008079290A3 (en) Stable buffered formulations containing polypeptides
DE60045752D1 (de) Modifizierte Faktor-VIIA-Polypeptide
ATE465748T1 (de) Vernetzte, nicht von pilzen kommende lipase enthaltende zusammensetzung und methoden zu deren verwendung
TR200001105T2 (tr) Değiştirilmiş K vitamini bağımlı polipeptidler.
HRP20080464T3 (en) Method for purifying fsh
DE602005016800D1 (de) Hif-prolylhydroxylase-aktivitätstest
ATE347611T1 (de) Automatischer apparat zum messen von wassertoxizität
DE60129137D1 (de) Modulierung durch il-tif/interleukin-21
AU2003304419A8 (en) Botulinum neurotoxin b receptors and use thereof
DE112005003750A5 (de) Verwendung von Moosen und/oder Flechten, Element und Verfahren zur Reduzierung des Feinstaubgehalts in der Luft
DE60013093D1 (de) Methoden und kits zum sequenzieren von polypeptiden
DE60015319D1 (de) Test zur gleichzeitigen messung von verschiedenen enzymatischen aktivitäten
WO2005086654A3 (en) Self-cleaving affinity tags and methods of use
ATE555126T1 (de) Relaxin-chimere polypeptide und deren herstellung und anwendung
MXPA02007787A (es) Moleculas trade y uso relacionado con las mismas.
ATE339683T1 (de) Verfahren zur detektion und konzentrationsbestimmung von schwefelfreien odoriermitteln in erd- oder brenngas
WO2005060998A3 (en) Methods of modulating cytokine activity; related reagents

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties